Skip to main content
. Author manuscript; available in PMC: 2023 Aug 15.
Published in final edited form as: Cancer Res. 2023 Feb 15;83(4):626–640. doi: 10.1158/0008-5472.CAN-22-0232

Figure 4. Safety profile of combined Anti- PDL1 and Anti-CTLA in MYC-HCC.

Figure 4.

A. Body weight and liver tests at end-of-treatment of MYC-HCC bearing mice treated with either IgG control (n=5) or PDL1 antibody (n=5) or CTLA4 antibody (n=5) or their combination (n=5).

B. Peripheral white cell counts at end-of-treatment of MYC-HCC bearing mice treated with either IgG control (n=5) or PDL1 antibody (n=5) or CTLA4 antibody (n=5) or their combination (n=5).

C. Histology and CD8 T cell infiltration in normal surrounding liver and colon tissue of mice treated with the 4 treatment groups. *p<0.05, **p<0.01.